{"doi":"10.1080/14737167.2016.1246186","title":"A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis","abstract":null,"journal":"Expert Review of Pharmacoeconomics & Outcomes Research","year":2016,"id":593449,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":81720,"name":"Christopher Black","orcid":null,"position":1,"is_corresponding":false},{"id":1518857,"name":"Her Hsin Tsai","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis","abstract":"INTRODUCTION: Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered: Research investigating the cost-effectiveness of vedolizumab is limited. This review considers data from the manufacturers, the evidence research group commissioned by NICE to conduct a single technology appraisal, and the decision of NICE itself to appraise what is currently known about the cost-effectiveness of vedolizumab for moderately to severely active ulcerative from a UK perspective. Expert commentary: Based on the very limited data currently available, it can be concluded that vedolizumab is a cost-effective option for those with moderately to severely active ulcerative colitis who are anti-TNFa naive; however, there is a need for further research comparing vedolizumab with other biologic therapies which may alter perceptions of cost-effectiveness.","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27726457","pmcid":null,"openalex_id":"https://openalex.org/W2530401429","authors":[],"funders":[],"total_grants":0,"fwci":0.5463,"citation_percentile":0.7722282,"influential_citations":0,"citation_trend":[{"year":2017,"count":1},{"year":2018,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1080/14737167.2016.1246186","host_type":"publisher"},{"url":"https://doi.org/10.1080/14737167.2016.1246186","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/27726457","host_type":"repository"}],"fields_of_study":["Inflammatory Bowel Disease","Microscopic Colitis","Eosinophilic Esophagitis","Antibodies, Monoclonal, Humanized","Colitis, Ulcerative","Cost-Benefit Analysis","Gastrointestinal Agents","Humans","Integrins","Severity of Illness Index","United Kingdom"],"mesh_terms":["Colitis, Ulcerative","Cost-Benefit Analysis","Gastrointestinal Agents","United Kingdom","Humans","Severity of Illness Index","Integrins","Antibodies, Monoclonal, Humanized"],"keywords":["Vedolizumab","Ulcerative colitis","Medicine","Cost effectiveness","Infliximab","Nice","Intensive care medicine","Internal medicine","Disease","Risk analysis (engineering)","Computer science","Inflammatory Bowel Disease","Cost-effectiveness"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T11:02:27.527246Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}